Welcome to our dedicated page for Celanese SEC filings (Ticker: CE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Celanese's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Celanese's regulatory disclosures and financial reporting.
Celanese Corp (CE) reports that SVP & CFO Chuck Kyrish purchased company common stock on August 14, 2026. Three non-derivative transactions labeled “Purchase in open market or private transaction” total 2,300 shares, at per-share prices ranging from $45.5050 to $45.5299, all held as direct ownership. The Rule 10b5-1 checkbox was not marked, so these purchases were not affirmed as made under a trading plan.
Ashley B. Duffie, SVP & GC of Celanese Corp, purchased 600 shares of common stock on 2026-08-11 in an open market or private transaction at $45.60 per share. Following this trade, Duffie directly holds 31,925 shares and indirectly holds 691.4868 shares through a 401(k) Plan.
Celanese Corp SVP Mark Christopher Murray purchased additional company shares. On 2026-08-11, he bought 2,153 shares of Common Stock in a purchase in open market or private transaction at $45.5199 per share. Following this transaction, he directly holds 30,432 shares of Celanese Common Stock.
Kissire Deborah J. reported acquisition or exercise transactions in this Form 4 filing.
Celanese Corp director Deborah J. Kissire received an award of 6.277 shares of phantom stock on August 10, 2026. Each phantom share represents the right to receive one share of common stock and reflects dividend equivalents on compensation deferred under the company’s 2008 Deferred Compensation Plan. Following this award, Kissire holds 9,310.054 phantom stock units, which are payable in common stock after her service as a director ends, as provided in the plan.
Rucker Kim K.W. reported acquisition or exercise transactions in this Form 4 filing.
Celanese Corp director Kim K.W. Rucker received an award of 8.705 phantom stock units on 2026-08-10, recorded at $44.4600 per unit. Each phantom stock unit represents the right to receive one share of common stock and reflects dividend equivalents on compensation deferred under the company’s 2008 Deferred Compensation Plan. Following this award, Rucker holds 12,909.224 phantom stock units, which are payable in shares of common stock after her service as a director ends, as provided in the plan.
Celanese Corp director Edward G. Galante reported two equity-based compensation awards. He received an annual grant of 1,930 shares of Common Stock as fully vested restricted stock units under the company's 2018 Global Incentive Plan, granted as compensation for prior service as Chair of the Board, bringing his direct Common Stock holdings to 27,983 shares. He also acquired 4.595 shares of phantom stock as dividend equivalents on deferred compensation under the 2008 Deferred Compensation Plan, increasing his phantom stock balance to 6,814.817 shares, payable in Common Stock following the end of his board service.
Celanese Corp director Kathryn Hill reported an acquisition of 0.7710 shares of phantom stock on 2026-08-10 at a reference value of $44.46 per share. These phantom stock units represent dividend equivalents on compensation deferred under Celanese’s 2008 Deferred Compensation Plan and are payable in an equivalent number of common shares as provided in the plan, bringing her reported phantom stock balance to 1,142.5400 units held directly.
Norges Bank, the central bank of Norway, reports beneficial ownership of Celanese Corp common stock on a passive basis. It reports holding 9,645,359 shares, representing 8.7955% of the outstanding common stock.
Norges Bank has sole voting power over 9,342,811 shares and no shared voting power. It has sole dispositive power over 9,342,811 shares and shared dispositive power over 302,548 shares. Certain shares are invested on behalf of the Government of Norway.
Celanese Corporation reported Q2 2026 net sales of $2,752 million, up from $2,532 million a year earlier. Net earnings attributable to Celanese were $125 million, with diluted EPS of $1.13 versus $1.80. For the first half, net sales reached $5,089 million and net earnings attributable to Celanese were $169 million.
Operating cash flow for the first six months was $285 million, while investing activities provided $366 million, helped by $493 million of proceeds from the Micromax business sale, which generated a $50 million gain. Financing uses totaled $549 million, including $621 million of long-term debt repayments. As of June 30, 2026, cash was $1,364 million and long-term debt, including current installments, carried at $12,013 million, with a $1.75 billion U.S. revolving credit facility fully available.
The company incurred $59 million of exit and shutdown costs tied mainly to closing its Lanaken, Belgium facility and expects an additional $60 million through 2027. Environmental remediation liabilities totaled $66 million, which management does not expect to be material to financial position. A quarterly dividend of $0.03 per share, totaling $3 million, was declared for payment in August 2026.
Celanese Corporation reported second quarter 2026 adjusted earnings per share of $2.45, including about $0.35 per share of non-cash transaction amortization, its highest level in nearly three years. Companywide operating EBITDA grew by more than 20% versus the prior-year period.
Engineered Materials delivered adjusted EBIT of $234 million and operating EBITDA of $335 million, with margins of 16% and 23%. Growth platforms performed strongly, with medical net sales up 19% and electronics up 11% year-over-year, while portfolio and footprint actions are expected to drive about $30 million of annualized cost savings and double-digit full-year adjusted EBIT growth despite inventory and divestiture headwinds.
The Acetyl Chain generated adjusted EBIT of $321 million and operating EBITDA of $385 million, at margins of 24% and 29%, as net sales rose 28% sequentially and 19% year-over-year, led by Western Hemisphere vinyl chain strength. Free cash flow was $140 million in the quarter, and management now targets 2026 free cash flow of $700–$800 million. The company repaid $508 million and $400 million of 2026 bonds using cash on hand and ended the quarter with total debt of $12.0 billion and net debt of $10.6 billion. Third quarter 2026 adjusted EPS is guided to approximately $1.35–$1.75, with full-year adjusted EPS expected to be about $6.00.